GEN Exclusives

More »

GEN News Highlights

More »
Oct 15, 2009

Genentech Taps Graffinity’s Fragment-Based Drug Discovery Technology

  • Genentech has obtained access to Graffinity Pharmaceuticals’ fragment-based drug discovery technology. Graffinity will receive technology access fees and optional payments for follow-up chemistry for the generation of novel, small molecule hits against a number of drug targets. 

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »